ADMA Biologics (NASDAQ:ADMA) Stock Price Down 10.8% - Here's What Happened

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report)'s stock price dropped 10.8% on Monday . The stock traded as low as $18.94 and last traded at $19.00. Approximately 3,666,268 shares traded hands during mid-day trading, an increase of 25% from the average daily volume of 2,936,019 shares. The stock had previously closed at $21.31.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Stock Up 2.9 %

The stock has a market capitalization of $5.28 billion, a price-to-earnings ratio of 79.82 and a beta of 0.53. The business has a 50-day moving average of $18.55 and a 200-day moving average of $18.26. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

Institutional Investors Weigh In On ADMA Biologics

A number of institutional investors have recently made changes to their positions in the stock. Perpetual Ltd acquired a new position in shares of ADMA Biologics in the 4th quarter worth approximately $62,300,000. Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics in the third quarter valued at approximately $61,858,000. Allspring Global Investments Holdings LLC lifted its stake in ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after purchasing an additional 2,613,482 shares in the last quarter. B Group Inc. purchased a new position in shares of ADMA Biologics during the fourth quarter worth $39,231,000. Finally, Raymond James Financial Inc. purchased a new position in shares of ADMA Biologics during the fourth quarter worth $19,076,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.